Calamos Wealth Management’s AstraZeneca AZN Stock Holding History

Calamos Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$798K	Sell	4,208 -23,019	-85%	-$4.33M	0.02%	248
2026 Q1	$5.37M	Buy	27,227 +11,452	+73%	+$2.21M	0.18%	91
2025 Q4	$2.9M	Buy	+15,775	New	+$2.77M	0.1%	109
2024 Q1	–	Sell	-9,137	Closed	-$1.23M	–	318
2023 Q4	$1.23M	Sell	9,137 -2,925	-24%	-$380K	0.08%	123
2023 Q3	$1.63M	Buy	12,062 +4,156	+53%	+$568K	0.12%	104
2023 Q2	$1.13M	Sell	7,906 -126	-2%	-$18.5K	0.08%	131
2023 Q1	$1.12M	Buy	8,032 +667	+9%	+$89.7K	0.09%	124
2022 Q4	$999K	Sell	7,365 -7,790	-51%	-$977K	0.08%	141
2022 Q3	$1.66M	Sell	15,155 -1,356	-8%	-$172K	0.14%	106
2022 Q2	$2.18M	Buy	+16,511	New	+$2.17M	0.19%	95

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Calamos Wealth Management's AZN Position: Q2 2026 in Review

Calamos Wealth Management reduced its AstraZeneca (AZN) stake by 85% in Q2 2026, selling an estimated $4.33M and leaving 4,208 shares worth $798K. The position accounts for 0.02% of the portfolio, ranked #248.

Calamos Wealth Management first reported a position in AZN in Q2 2022 and has held it in 10 quarters since. The position peaked at $5.37M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Calamos Wealth Management held 4,208 shares of AstraZeneca worth $798K as of Q2 2026.
Calamos Wealth Management sold 23,019 AstraZeneca shares in Q2 2026, an estimated $4.33M.
AstraZeneca made up 0.02% of Calamos Wealth Management's portfolio in Q2 2026, its #248 holding.
Calamos Wealth Management first reported a position in AstraZeneca in Q2 2022 and has held it in 10 quarters since.
Calamos Wealth Management's AstraZeneca position peaked at $5.37M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.